Skip to main content
Evidence Snapshot

Amyloid-beta precursor protein

CHEMBL2487 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:31Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2487
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Amyloid-beta precursor protein as ChEMBL target CHEMBL2487, mapped to UniProt P05067. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Amyloid-beta precursor protein
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2487
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P05067
Amyloid-beta precursor protein
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Amyloid-beta precursor protein matters

As of 2026-09-13

Amyloid-beta precursor protein is reviewed as Amyloid-beta precursor protein (UniProt P05067); Amyloid-beta precursor protein shows approved-linked disease relevance led by Alzheimer disease. 4 more disease programs remain visible in the same review block.; 13 linked drugs keep this evidence frame grounded.; the current evidence base includes 17 approved drugs, 5302 compounds, and 1689 assays, with lead potency reaching pChEMBL 10.2.

Disease context
Alzheimer disease

Amyloid-beta precursor protein shows approved-linked disease relevance led by Alzheimer disease. 4 more disease programs remain visible in the same review block. 13 linked drugs keep the rationale reviewable. 4 additional disease programs remain visible in the same card. Linked drugs include ADUCANUMAB, AMILOMOTIDE, BAPINEUZUMAB.

Start review with Alzheimer disease because it currently carries approved-linked support. Linked drugs include ADUCANUMAB, AMILOMOTIDE, BAPINEUZUMAB, CRENEZUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 13 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 17 approved drugs, 5302 compounds, and 1689 assays for this target. The dominant activity type is IC50. CHEMBL384465 is the current potency anchor at pChEMBL 10.2.

Use CHEMBL384465 as the tractability anchor when discussing potency (pChEMBL 10.2).

Activity source · ChEMBL 36 via Core Engine
17 approved pChEMBL 10.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Amyloid-beta precursor protein matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P05067, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Alzheimer disease is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

5302
Total Compounds
1689
Total Assays
17
Approved Drugs
IC50: 2070.0, KI: 579.0, EC50: 148.0, KD: 130.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL384465
 10.2 Ki —
No preferred name
CHEMBL2152914
 10.0 IC50 —
No preferred name
CHEMBL74704
 10.0 Ki —
No preferred name
CHEMBL76112
 9.9 Ki —
No preferred name
CHEMBL300172
 9.8 Ki —

Approved Drugs

Structure Compound First Approval
FLORBETABEN F18
CHEMBL566752
 2014
FLUTEMETAMOL F 18
CHEMBL2042122
 2013
FLUTEMETAMOL
CHEMBL579205
 2013
FLORBETAPIR F 18
CHEMBL1774461
 2012
FLORBETAPIR
CHEMBL1908919
 2012
METHYLENE BLUE ANHYDROUS
CHEMBL405110
 2011
METHYLENE BLUE CATION
CHEMBL191083
 2011
TACRINE
CHEMBL95
 1993
RETINOL
CHEMBL986
 1982
TRETINOIN
CHEMBL38
 1971
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:31Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2487